Leases

6 Months Ended

Jun. 30, 2025

LEASES

On November 15, 2021, Cumberland entered into a lease (the "Broadwest Lease"), pursuant to which the Company leases approximately 16,903 rentable square feet of space (the "Leased Premise") at the Broadwest office campus located in Nashville, Tennessee with 1600 West End Avenue Partners, LLC (the "Landlord"). The Leased Premise serves as the Company's corporate headquarters. The initial term of the Lease is one hundred fifty-seven (157) months, with two consecutive options to renew for a period of 5 years each, with the commencement date of October 25, 2022. This lease currently expires in November 2035.

The Company is responsible for paying rent to the Landlord under the lease beginning three months after the commencement date. The Company pays a base rent of $33.06 per square foot of rentable space with a gradual rental rate increase of 2.5% for each year thereafter of the prior year's base rental. In addition to the monthly base rent, the Company is responsible for its percentage share of the operating expenses of the building. The lease also provided for a tenant improvement allowance which was used to build out the space.

On October 24, 2022, CET provided the notice of exercise to extend the lease with The Gateway to Nashville, LLC (the "Gateway Lease") for five years. The lease is for approximately 14,200 square feet of wet laboratory and office space in Nashville, Tennessee where CET operates the CET Life Sciences Center. The wet laboratory and office space is leased through April 2028. The Company also subleases a portion of the space under this lease.

Also included within the right-of-use assets are start up expenditures related to new supply agreements with Nephron Pharmaceuticals Corporation ("Nephron") for our Vaprisol product and Kindos Pharmaceuticals Co., Ltd. ("Kindos") for our Vibativ product. These expenditures are classified as embedded leases resulting in right-of-use assets to be amortized over the life of the contracts. As of June 30, 2025, the right-of-use assets for Nephron and Kindos was $0.7 million and $1.4 million, respectively, and included in the total right-of-use assets of $7.1 million.

Operating lease liabilities were recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for lease incentives and initial direct costs. As the Company’s leases do not contain implicit borrowing rates, the incremental borrowing rates were calculated based on information available at the commencement date of each lease. Incremental borrowing rates reflect the Company’s estimated interest rates for collateralized borrowings over similar lease terms.

The weighted-average remaining lease term for the Broadwest Lease and Gateway Lease is 9.2 years and 10.0 years at June 30, 2025 and June 30, 2024, respectively. The weighted-average incremental borrowing rate used to discount the present value of the remaining lease payments for both leases is 9.37% and 9.38% at June 30, 2025 and December 31, 2024, respectively.

Lease Position

At June 30, 2025 and December 31, 2024, the Company's lease assets and liabilities were as follows:


Right-of-Use Assets	June 30, 2025		December 31, 2024
Operating lease right-of-use assets	$	7,125,408	$	6,176,923


Lease Liabilities	June 30, 2025		December 31, 2024
Operating lease current liabilities	$	386,077	$	356,508
Operating lease non-current liabilities	4,714,183		4,939,739
Total	$	5,100,260	$	5,296,247

As of June 30, 2025, cumulative future minimum sublease income under non-cancelable operating subleases totals approximately $0.2 million which includes the 90-day notice required for lease termination. Future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:


Maturity of Lease Liabilities at June 30, 2025	Operating Leases
2025	395,658
2026	909,911
2027	934,180
2028	740,791
2029	650,766
After 2029	4,196,635
	7,827,941
Less: Interest	2,727,681
Present value of lease liabilities	$	5,100,260

Rent expense is recognized over the expected term of the lease, including renewal option periods, if applicable, on a straight-line basis as a component of general and administrative expense. Rent expense and sublease income were as follows:


	Three months ended June 30,				Six months ended June 30,
	2025		2024		2025		2024
Rent expense	$	363,583	$	344,418	$	718,335	$	699,482

Sublease income	$	162,797	$	123,230	$	321,426	$	287,913

CUMBERLAND PHARMACEUTICALS INC 10-Q